Affordable Access

deepdyve-link
Publisher Website

SGLT2 inhibitors in the treatment of type 2 diabetes

Authors
  • Hasan, Farhad M.
  • Alsahli, Mazen
  • Gerich, John E.1, 2, 3
  • 1 University of Virginia School of Medicine
  • 2 University of Toronto Faculty of Medicine
  • 3 University of Rochester School of Medicine
Type
Published Article
Journal
Diabetes Research and Clinical Practice
Publisher
Elsevier
Publication Date
Jan 01, 2014
Accepted Date
Feb 19, 2014
Identifiers
DOI: 10.1016/j.diabres.2014.02.014
Source
Elsevier
Keywords
License
Unknown

Abstract

The kidney plays an important role in glucose homeostasis via its production, utilization, and, most importantly, reabsorption of glucose from glomerular filtrate which is largely mediated via the sodium glucose co-transporter 2 (SGLT2). Pharmacological inhibition of SGLT2 increases urinary glucose excretion and decreases plasma glucose levels in an insulin-independent manner. Agents that inhibit SGLT2 represent a novel class of drugs, which has recently become available for treatment of type 2 diabetes. This article summarizes the rationale for use of these agents and reviews available clinical data on their efficacy, safety, and risks/benefits.

Report this publication

Statistics

Seen <100 times